Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F. Poels KE, et al. Among authors: makhnin a. Nat Commun. 2021 Jun 17;12(1):3697. doi: 10.1038/s41467-021-23912-4. Nat Commun. 2021. PMID: 34140482 Free PMC article. Clinical Trial.
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
Yu HA, Schoenfeld AJ, Makhnin A, Kim R, Rizvi H, Tsui D, Falcon C, Houck-Loomis B, Meng F, Yang JL, Tobi Y, Heller G, Ahn L, Hayes SA, Young RJ, Arcila ME, Berger M, Chaft JE, Ladanyi M, Riely GJ, Kris MG. Yu HA, et al. Among authors: makhnin a. JAMA Oncol. 2020 Jul 1;6(7):1048-1054. doi: 10.1001/jamaoncol.2020.1260. JAMA Oncol. 2020. PMID: 32463456 Free PMC article. Clinical Trial.
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib.
Choudhury NJ, Makhnin A, Tobi YY, Daly RM, Preeshagul IR, Iqbal AN, Ahn LS, Hayes SA, Heller G, Kris MG, Riely GJ, Yu HA. Choudhury NJ, et al. Among authors: makhnin a. JCO Precis Oncol. 2021 Apr 22;5:PO.21.00005. doi: 10.1200/PO.21.00005. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250398 Free PMC article. Clinical Trial.
Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F. Poels KE, et al. Among authors: makhnin a. Nat Commun. 2022 Sep 23;13(1):5579. doi: 10.1038/s41467-022-33355-0. Nat Commun. 2022. PMID: 36151107 Free PMC article. No abstract available.
Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers.
Mondaca S, Offin M, Borsu L, Myers M, Josyula S, Makhnin A, Shen R, Riely GJ, Rudin CM, Ladanyi M, Yu HA, Li BT, Arcila ME. Mondaca S, et al. Among authors: makhnin a. Acta Oncol. 2019 Nov;58(11):1634-1639. doi: 10.1080/0284186X.2019.1645354. Epub 2019 Jul 26. Acta Oncol. 2019. PMID: 31347936 Free PMC article.
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, Paik PK, Chaft JE, Kris MG, Jeon JO, Borsu LA, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Shaffer T, Garg K, DiPasquo D, Raymond CK, Lim LP, Li M, Hellmann MD, Drilon A, Riely GJ, Rusch VW, Jones DR, Rimner A, Rudin CM, Isbell JM, Li BT. Sabari JK, et al. Among authors: makhnin a. J Natl Cancer Inst. 2019 Jun 1;111(6):575-583. doi: 10.1093/jnci/djy156. J Natl Cancer Inst. 2019. PMID: 30496436 Free PMC article.
Multiplex SuperSelective PCR Assays for the Detection and Quantitation of Rare Somatic Mutations in Liquid Biopsies.
Vargas DY, Tyagi S, Marras SAE, Moerzinger P, Abin-Carriquiry JA, Cuello M, Rodriguez C, Martinez A, Makhnin A, Farina A, Patel C, Chuang TL, Li BT, Kramer FR. Vargas DY, et al. Among authors: makhnin a. J Mol Diagn. 2022 Mar;24(3):189-204. doi: 10.1016/j.jmoldx.2021.11.006. Epub 2021 Dec 23. J Mol Diagn. 2022. PMID: 34954118 Free PMC article.
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
Guo R, Offin M, Brannon AR, Chang J, Chow A, Delasos L, Girshman J, Wilkins O, McCarthy CG, Makhnin A, Falcon C, Scott K, Tian Y, Cecchi F, Hembrough T, Alex D, Shen R, Benayed R, Li BT, Rudin CM, Kris MG, Arcila ME, Rekhtman N, Paik P, Zehir A, Drilon A. Guo R, et al. Among authors: makhnin a. Clin Cancer Res. 2021 Feb 1;27(3):799-806. doi: 10.1158/1078-0432.CCR-20-2861. Epub 2020 Nov 10. Clin Cancer Res. 2021. PMID: 33172896 Free PMC article.
14 results